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Background
Pancreatic ductal adenocarcinoma (PDAC) is an aggres-
sive cancer that has a 5-year survival rate of less than
7% and is ultimately refractory to most treatments. An
assessment of immunologic factors relevant to disease
has not been performed in a comprehensive manner for
treatment naïve patients to date. We hypothesized that
systemic immunologic activation and/or immunosup-
pression would predict overall survival (OS) in treatment
naïve PDAC patients.
Methods
To test this hypothesis, peripheral blood was collected from
73 patients presenting with previously untreated metastatic
PDAC who went on to be treated in a randomized multi-
center Phase II trial (NCT01280058: Carboplatin and pacli-
taxel with or without viral therapy in treating patients with
recurrent or metastatic pancreatic cancer).
Results
There was no significant difference in outcomes between
treatment arms in the subsequent clinical trial, and across
both arms OS was 7.5 months. Extensive immunologic
profiling was conducted to assess relationships between
overall survival and the level of soluble plasma biomarkers
(cytokines, chemokines and growth factors) or detailed
immune cell phenotypes as measured by flow cytometry at
baseline, prior to any treatment. Higher levels IL-6 and
IL-10, prominent immunosuppressive cytokines were
negatively associated with OS (p = 0.008 and 0.020, respec-
tively; HR = 1.157 and 1.277, respectively). Conversely,
higher levels of the monocyte chemoattractant MCP-1
were associated with significantly longer OS (p = 0.045;
HR = 0.687). Patients with a greater proportion of antigen-
experienced T cells (CD45RO+) had longer overall survival
(CD4 p-value = 0.032; CD8 p-value = 0.036; HR = 0.357
and 0.614, respectively). While greater expression of the
T cell checkpoint molecule CTLA-4 on CD8+ T cells was
associated with significantly shorter overall survival (p =
0.0198; HR = 1.533), the TIM3 molecule had a positive
association with survival when expressed on CD4+ T cells
(p = 0.0269; HR = 0.622). Overall, these data identify several
immunological predictors of overall survival in a treatment
naïve cohort of patients with metastatic pancreatic ductal
adenocarcinoma.
Conclusions
This supports the idea that therapies targeting or modify-
ing the immune system could improve future PDAC treat-
ment outcomes. To our knowledge, this work represents
the largest cohort and most comprehensive immune pro-
filing of treatment-naïve metastatic PDAC patients to date.
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